Tags : #EULAR

Biotech

Eli Lilly to Present Data of Taltz (ixekizumab) for Patients

Shots: Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV, 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as ACR50 & PASI 100 @24wks. The study compares Taltz and Humira in subgroups of patients on monothx./ concomitant MTX/ concomitant MTX along with csDMARD including […]Read More

Pharma

AbbVie Reports Results of Upadacitinib in Two P-III Studies for

Shots: The P-III SELECT EARLY & SELECT-COMPARE study results involve assessing of Upadacitinib (15mg/30mg,qd) as monothx. & Upadacitinib + MTX (15mg, qd) vs MTX & adalimumab + MTX in patients with rheumatoid arthritis respectively The P-III SELECT EARLY & SELECT-COMPARE study results: @48wks. improvement in symptoms of rheumatoid arthritis measured by ACR20/50; maintain clinical remission […]Read More